DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Biologics IP - A Strategic Review (TechVision)" report to their offering.
This study provides a strategic overview of the patent activity of the 13 major pharma-biotech companies in the area of biologics. The biologics patent portfolios of these companies were analyzed and segmented by biologics type (e.g., peptides, antibodies, vaccines etc.) and therapeutic area for competitive benchmarking.
This study will help pharma-biotech companies understand the competitive landscape and the available white space from patenting perspective.
Key Topics Covered:
1. Executive Summary
2. Research Objective and Background
3. Research Scope and Methodology
4. Biologics Patent Portfolios of the Top 13 Major Pharma Companies
5. Overview of Biologics Patent Portfolio
Companies Mentioned
- AbbVie
- Amgen
- AstraZeneca
- Bayer HealthCare
- Bristol-Myers Squibb
- Eli Lilly
- GSK
- Merck
- Novartis
- Novo Nordisk
- Pfizer
- Roche
- Sanofi
For more information about this report visit http://www.researchandmarkets.com/research/6mqbdb/biologics_ip_a
Related Topics: Biopharmaceuticals
